UNSPSC 51123203: Aprindine hydrochloride

This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PB5EKT7Q2V, chemically known as 1,3-propanediamine, n-(2, 3-dihydro-1h-inden-2-yl)-n,n-diethyl-n-phenyl-, monohydrochloride but more generally known as aprindine hydrochloride, which bears US NIH Compound Identifier 2218. European Medicines Agency schedules Aprindine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00565MIG.

UNSPSC 51123203 Aprindine hydrochloride, a Commodity code, identifies a single pharmaceutical active ingredient but state and local governments actually buy advanced life support medications and generic pharmaceuticals through cooperative purchasing vehicles and direct municipal procurement. Recent solicitations show that the code captures emergency medical supplies for fire and rescue services, multi-state generic pharmaceutical distribution networks, and pharmacy benefit program implementations. Issuing bodies include city purchasing departments (Tampa), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves supplying finished pharmaceutical products—epinephrine, labetalol, adenosine, and diltiazem for emergency response—as well as generic multi-source drugs and over-the-counter products distributed through authorized wholesalers to state and local healthcare facilities.

Activity clusters in Florida, Texas, and Minnesota, with MMCAP drawing participation from Oregon and other alliance member states. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring vendors to supply four specific medication line items with nine-month minimum expiration dates and ten-day delivery, with a one-year term and optional two-year renewals; Tampa designated the procurement as sheltered for Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and certify cGMP and Drug Supply Chain Security Act compliance. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 as a market-intelligence tool to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.